Your email has been successfully added to our mailing list.

×
0.016949152542373 0.0429986962190353 -0.0117340286831812 -0.0612777053455019 -0.165567144719687 -0.0951760104302477 -0.191655801825293 -0.0221642764015645
Stock impact report

Tiziana submits patent application for expanded use of Foralumab in COVID-19 [Seeking Alpha]

Tiziana Life Sciences Ltd - Common Shares (TLSA) 
Company Research Source: Seeking Alpha
Tiziana Life Sciences(NASDAQ:TLSAsoars 48%submitting a patent applicationThe company has a worldwide exclusive license for nasal administration of Foralumab and other anti-CD3 mAbs for the treatment of neurodegenerative and other diseases.Based on animal studies, the nasal and oral administration of Foralumab offers the potential for the immunotherapy of autoimmune and inflammatory diseases in a safe manner by the induction of regulatory T-cells. Show less Read more
Impact Snapshot
Event Time:
TLSA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
TLSA alerts

from News Quantified
Opt-in for
TLSA alerts

from News Quantified